Modulation of Different Signaling Pathways in Liver Cancer by Arsenic Trioxide

The greatest health concern facing the globe today is still cancer. In order to defeat various malignancies, researchers are now racing to develop effective anticancer tactics to stop this global tidal wave of cancer in both its extremely early and advanced stages. However, very few specific treatments or medications have so far been proven to be effective. An old medication called arsenic trioxide (As₂O₃) has recently gained resurgence as a treatment for several cancers. Arsenic is generally recognized as a naturally hazardous material that can cause a wide range of harmful adverse reactions. Despite its present image as a poison, arsenic is one of the world’s oldest medicines and has been used for ages to treat conditions ranging from cancer to infections. Due to its treatable antitumor impact in acute promyelocyticleukaemia (APL) patients, it attracted a lot of attention from people worldwide. The anticancer medication most frequently used among the arsenicals is (ATO) arsenic trioxide. Numerous studies have been carried out to comprehend the molecular pathways through which ATO induces or facilitates the apoptotic signalling pathway in cancer cells. The treatment of Hepatocellular Carcinoma (HCC) and other cancers with novel, currently available arsenic-based therapeutics is discussed here. We also discussed the novel molecular mechanism that underlies the combined therapy’ induction of apoptosis.